Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of BXCL501 to Treat Symptoms of Acute Opioid Withdrawal in Patients With Opioid Use Disorder Who Are Physically Dependent on Opioids

NCT04470050 is registered in ClinicalTrials.gov with BioXcel Therapeutics Inc as lead sponsor.

NCT NCT04470050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04470050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of BXCL501 to Treat Symptoms of Acute Opioid Withdrawal in Patients With Opioid Use Disorder Who Are Physically Dependent on Opioids
Lead sponsor
BioXcel Therapeutics Inc
Phase
Phase 1/2
Overall status
Completed
Start date
June 9, 2020
Completion date
February 18, 2021
Enrollment
225 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

opioid withdrawal